RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced that Ken Song, M.D., President and CEO of the Company, will be presenting at the 41^st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023.

J.P. Morgan Healthcare Conference

Date: Monday, January 9, 2023

Time: 2:00 p.m. - 2:25 p.m. PST

Location: The Westin St. Francis – Golden Gate Room

About RayzeBio

RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company is backed by a syndicate of sophisticated healthcare investors and was established in 2020. For additional information, please visit www.rayzebio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230104005346/en/